Palonosetron-d3 (hydrochloride)

Palonosetron-d3 (hydrochloride)

• CAS Number: 1246816-81-8
• UNSPSC Description: Palonosetron-d3 (hydrochloride) is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV)[1][2].
• Target Antigen: 5-HT Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;Neuronal Signaling;Others
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C1C2=C3[C@@](C(N1[C@]4(C5CCN(C4)CC5)[2H])([2H])[2H])(CCCC3=CC=C2)[H].Cl
• Molecular Weight: 335.89
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K.
 Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase.
 J Pharm Biomed Anal. 2011 Sep 10;56(2):429-35.|[3]Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H.
 Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist.Nihon Yakurigaku Zasshi. 2010 Aug;136(2):113-20.|[4]Ruhlmann C, Herrstedt J.
 Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
 Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48.|[5]Trissel LA, Trusley C, Ben M, Kupiec TC.
 Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.
 Am J Health Syst Pharm. 2007 Jun 1;64(11):1209-13.|[6]Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.J. Med. Chem., 1993, 36 (18), pp 2645-2657
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported